Cartesian Therapeutics
RNAC
54 hedge funds and large institutions have $28M invested in Cartesian Therapeutics in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 26 increasing their positions, 16 reducing their positions, and 16 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 16
0.14% less ownership
Funds ownership: 1.7% → 1.56% (-0.14%)
17% less funds holding
Funds holding: 65 → 54 (-11)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
69% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 16
84% less capital invested
Capital invested by funds: $178M → $28M (-$150M)
90% less call options, than puts
Call options by funds: $1K | Put options by funds: $10K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$2.11M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
+$1.32M |
| 3 |
JP Morgan Chase
New York
|
+$971K |
| 4 |
Renaissance Technologies
New York
|
+$754K |
| 5 |
Two Sigma Investments
New York
|
+$713K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.89M |
| 2 |
SRF
Silver Rock Financial
Los Angeles,
California
|
-$2.5M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.22M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.1M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.64M |
RNAC Hedge Fund Activity: Q4 2018 in Review
54 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2018, worth a combined $28M — down 84% from $178M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RNAC and 5 opened new positions — a net loss of 11 holders — while 16 trimmed existing stakes and 26 added.
The largest buyer was Man Group, adding an estimated $2.11M. The largest seller was Vanguard Group, cutting an estimated $2.89M.
- 54 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2018, down from 65 in Q3 2018.
- Funds reported $28M of Cartesian Therapeutics stock for Q4 2018, down 84% quarter-over-quarter.
- 5 funds opened new Cartesian Therapeutics positions in Q4 2018 and 16 closed out, a net change of -11 holders.
- The largest Cartesian Therapeutics buyer in Q4 2018 was Man Group, an estimated $2.11M added.
- The largest Cartesian Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $2.89M sold.
Based on aggregated 13F filings for Q4 2018.